Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 603

[246] Gyongyossy-Issa MIC, Muller W, Devine DV. The covalent coupling of Arg-Gly-Asp-
containing peptides to liposomes: purification and biochemical function of the lipopep-
tide. Arch Biochem Biophys 1998;353:101-8.
[247] Liguori L, Marques B, Villegas-Mendez A, Rothe R, Lenormand J. Liposomes-mediated
delivery of pro-apoptotic therapeutic membrane proteins. J Control Release 2008;126:
217-27.
[248] Woodle MC, Storm G, Newman MS, Jekot JJ, Collins LR, Martin FJ, et al. Prolonged
systemic delivery of peptide drugs by long-circulating liposomes: illustration with vaso-
pressin in the Brattleboro rat. Pharm Res 1992;9:260-5.
[249] Torchillin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev
Drug Discovery 2005;4:145-60.
[250] Storm G, Koppenhagen F, Heeremans A, Vingerhoeds M, Woodle MC, Crommelin
DJA. Novel developments in liposomal delivery of peptides and proteins. J Control
Release 1995;36:19-24.
[251] Klegerman ME, Zou Y, McPherson DD. Fibrin targeting of echogenic liposomes with
inactivated tissue plasminogen activator. J Liposome Res 2008;18:95-112.
[252] Krzemienieck K, Szpyt E, Rashedi I, Gawron K, Los M. Targeting of solid tumors and
blood malignancies by antibody-based therapies-EGFR-pathway as an example. Cent
Eur J Biol 2006;1:167-82.
[253] Hantel C, Lewrick F, Schneider S, Zwermann O, Perren A, Reincke M, et al. Anti insu-
lin-like growth factor I receptor immunoliposomes: a single formulation combining two
anticancer treatments with enhanced therapeutic efficiency. J Clin Endocrinol Metab
2009;95:943-52.
[254] Fonseca MJ, Jagtenberg JC, Haisma HJ, Storm G. Liposome-mediated targeting of
enzymes to cancer cells for site-specific activation of prodrugs: comparison with the
corresponding antibody-enzyme conjugate. Pharm Res 2003;20:423-8.
[255] Oh KS, Han SK, Lee HS, Koo HM, Kim RS, Lee KE, et al. Core/Shell nanoparticles
with lecithin lipid cores for protein delivery. Biomacromolecules 2006;7:2362-7.
[256] Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of
uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res
1997;14:1568-73.
[257] Song C, Labhasetwar V, Cui X, Underwood T, Levy RJ. Arterial uptake of biodegrad-
able nanoparticles for intravascular local drug delivery: results with an acute dog model.
J Controlled Release 1998;54:201-11.
[258] Moghimi SM, Hunter AC, Murray JC. Long-circulating and target specific nanoparti-
cles: theory to practice. Pharmacol Rev 2001;53:283-318.
[259] Schrier JA, DeLuca PP. Porous bone morphogenetic protein-2 microspheres: polymer
binding and in vitro release. AAPS Pharm Sci Tech 2001;2:66-72.
[260] Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparations of biodegradable
nanospheres of water-soluble and insoluble drugs with DL-lactide/glycolide copolymer
by a novel spontaneous emulsification solvent diffusion method, and the drug release
behavior. J Control Release 1993;25:89-98.
[261] Jung T, Kamm W, Breitenbach A, Klebe G, Kissel T. Loading of tetanus toxoid to bio-
degradable nanoparticles from branched poly(sulfobutyl-polyvinyl alcohol)--(lactide-
co -glycolide) nanoparticles by protein adsorption: a mechanistic study. Pharm Res
2002;19:1105-13.
[262] Chouinard F, Buczkowski S, Lenaerts V. Poly (alkylcyanoacrylate) nanocapsules:
physicochemical characterization and mechanism of formation. Pharm Res 1994;11:
869-74.